Yumanity Therapeutics | Evaluate

January 24, 2022

Early-stage US clinical holds spread

September 07, 2021

As Forte fails, who might yet improve the image of reverse mergers?

Among developers that arrived on the market via reverse mergers, big success stories are hard to find.

August 25, 2020

Yumanity finds a shell in Proteostasis

Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.